During the last session, Praxis Precision Medicines Inc (NASDAQ:PRAX)’s traded shares were 0.45 million, with the beta value of the company hitting 2.69. At the end of the trading day, the stock’s price was $33.79, reflecting an intraday gain of 13.29% or $3.96. The 52-week high for the PRAX share is $91.83, that puts it down -171.77 from that peak though still a striking 20.98% gain since the share price plummeted to a 52-week low of $26.70. The company’s market capitalization is $681.32M, and the average intraday trading volume over the past 10 days was 0.64 million shares, and the average trade volume was 542.65K shares over the past three months.
Praxis Precision Medicines Inc (PRAX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.45. PRAX has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -3.2.
Praxis Precision Medicines Inc (NASDAQ:PRAX) trade information
Praxis Precision Medicines Inc (PRAX) registered a 13.29% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 13.29% in intraday trading to $33.79, hitting a weekly high. The stock’s 5-day price performance is 18.69%, and it has moved by -12.51% in 30 days. Based on these gigs, the overall price performance for the year is -35.53%. The short interest in Praxis Precision Medicines Inc (NASDAQ:PRAX) is 1.99 million shares and it means that shorts have 2.95 day(s) to cover.
The consensus price target of analysts on Wall Street is $85, which implies an increase of 60.25% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $73 and $120 respectively. As a result, PRAX is trading at a discount of -255.13% off the target high and -116.04% off the low.
Praxis Precision Medicines Inc (PRAX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -84.43% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 183.1k as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 195.7k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 431k and 357k respectively. In this case, analysts expect current quarter sales to shrink by -57.52% and then drop by -45.18% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 8.54%. While earnings are projected to return -20.76% in 2025, the next five years will return -0.75% per annum.
PRAX Dividends
Praxis Precision Medicines Inc is due to release its next quarterly earnings on 2025-Feb-27. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Praxis Precision Medicines Inc (NASDAQ:PRAX)’s Major holders
Praxis Precision Medicines Inc insiders own 0.46% of total outstanding shares while institutional holders control 112.11%, with the float percentage being 112.63%. BLACKROCK INC. is the largest shareholder of the company, while 224.0 institutions own stock in it. As of 2024-06-30, the company held over 1.29 million shares (or 6.874% of all shares), a total value of $53.52 million in shares.
The next largest institutional holding, with 1.24 million shares, is of RA CAPITAL MANAGEMENT, L.P.’s that is approximately 6.5638% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $51.1 million.
Also, the Mutual Funds coming in first place with the largest holdings of Praxis Precision Medicines Inc (PRAX) shares are SMALLCAP WORLD FUND INC and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. Data provided on Dec 31, 2024 indicates that SMALLCAP WORLD FUND INC owns about 888.06 shares. This amounts to just over 4.40 percent of the company’s overall shares, with a $30.01 million market value. The same data shows that the other fund manager holds slightly less at 562.19, or about 2.79% of the stock, which is worth about $19.0 million.
